Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018

Posted on: 28 Dec 17

Zug, Switzerland, Dec. 28, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide an update on its development program with AM-111 for the treatment of acute inner ear hearing loss on Thursday, January 4, 2018. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time), featuring Hinrich Staecker, MD, PhD, Professor of Otolaryngology at the University of Kansas Medical Center. Dr Staecker trained at Albert Einstein College of Medicine and Massachusetts Eye and Ear infirmary and has been in practice for over 25 years with a primary focus on neurotology and otology. His research activities are mainly dedicated to developing treatments for hearing loss. Dr. Staecker has published numerous articles and book chapters.

To participate in this conference call, dial 1-800-281-7973 (USA) or +1-646-828-8156 (International), and enter passcode 2284504. A live webcast of the conference call can be accessed in the Investor Relations section of the Auris Medical website at A replay will be available approximately two hours following the live call.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology. The company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for the treatment of vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Capital Market under the symbol "EARS."

Investor contact: Daniel Ferry, LifeSci Advisors, 1-617-535-7746,  


Last updated on: 29/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.